Bris­tol-My­ers takes a stake in Taris Bio­med­ical; Zai Lab, Five Prime strike a deal to de­vel­op tu­mor im­munother­a­py in Chi­na

Bris­tol-My­ers Squibb has tak­en a stake in Taris Bio­med­ical as part of their new col­lab­o­ra­tion on a Phase Ib study of a com­bo ap­proach …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.